Measures to curb Malpractices in Pharma Companies

1. At a Glance

• UCPMP 2024 = government-notified code regulating how pharma firms market drugs to doctors / Registered Medical Practitioners (RMPs) to prevent unethical inducements [S1][S2].
• Notified by Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, on 12 March 2024 [S1][S2].
• Topical for GS-II (governance/health) & GS-IV (ethics in private sector, conflict of interest) — links to drug pricing, medical ethics, consumer protection.

2. Why in the News

• DoP issued a press communication on 27 March 2026 reiterating measures under UCPMP 2024 to curb pharma malpractices, including the operational framework for complaints and penalties [S1].
• Backdrop: recurring controversies over freebies, foreign trips, and gifts to doctors influencing prescription behaviour.

3. Background & Evolution

• 2012: First UCPMP issued as a voluntary code by DoP; widely criticised for being non-binding [S2].
• CBDT Circular No. 5/2012 & later Apex Laboratories vs DCIT (2022, SC) held that freebies to doctors are not deductible business expenditure under Sec. 37(1), IT Act (general knowledge — not cited from search).
• Various extensions of the voluntary code through 2014–2023; demands grew for a statutory code [S2].
• 12 March 2024: DoP notified the revised UCPMP 2024 with an operational complaints + penalty mechanism [S1][S2].

4. Core Static Facts

• Name: Uniform Code for Pharmaceuticals Marketing Practices (UCPMP) 2024 [S1].
• Notified by: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [S1].
• Date of notification: 12 March 2024 [S1][S2].
• Scope: Governs interactions between pharma companies / medical representatives and doctors / RMPs; covers textual and audio-visual promotional material, free samples, gifts, hospitality, brand reminders [S2].
• Two-tier grievance architecture [S2]:
• Ethics Committee for Pharmaceutical Marketing Practices (ECPMP) — constituted by pharmaceutical associations to handle complaints.
• Apex Ethics Committee for Pharmaceutical Marketing Practices (AECPMP) — review body.
• Prohibitions [S1][S2]: gifts, monetary benefits, hospitality, or travel to HCPs or their family members.
• Disclosure requirement: Self-declaration of code adherence; disclosure of expenditure on CMEs / CPDs (Continuing Medical Education / Professional Development) [S2].
• Penalties [S2]: recovery of value of gift from concerned person; corrective statement in media for non-compliant promotional material; referral for action under existing laws.

5. Multi-Dimensional Analysis

Ethical / Governance - Tackles conflict of interest between prescriber autonomy and commercial inducement [S1][S2]. - Holds pharma companies vicariously accountable for actions of medical representatives & employees [S2].

Economic - Inflates drug prices when promotional spend (freebies, foreign trips) is loaded onto MRP — UCPMP indirectly supports affordability agenda [S1]. - Complements National Pharmaceutical Pricing Authority (NPPA) price-control function (general).

Legal / Constitutional - UCPMP remains an executive code, not a statute — enforceability gap; uses self-regulation by industry associations rather than statutory penalties [S2]. - Synergises with Sec. 37(1) Income Tax Act disallowance of freebie expenditure and with Drugs and Cosmetics Act, 1940.

Administrative - Implementation rests on industry-association-run ECPMPs, raising concerns of self-policing weakness [S2]. - DoP retains oversight via AECPMP appellate route and reference to other ministries for action [S2].

Social / Health - Aims to protect patients from irrational prescribing driven by gifts; strengthens trust in doctor-patient relationship [S1].

6. Recent Developments (last 12-18 months)

• 12 March 2024 — UCPMP 2024 notified, replacing the 2014 voluntary code [S1][S2].
• 2024 — Year-End Review by DoP highlighted UCPMP rollout among reform measures [S3].
• 2024 — Central Consumer Protection Authority (CCPA) issued guidelines on misleading advertisements relevant to health-product claims [S4].
• 27 March 2026 — PIB communication reiterating UCPMP enforcement framework [S1].

7. Prelims Hooks

• UCPMP 2024 notified on 12 March 2024 by Department of Pharmaceuticals [S1][S2].
• Parent ministry: Ministry of Chemicals and Fertilizers [S1].
• UCPMP prohibits gifts/hospitality to family members of HCPs (not just HCPs themselves) [S1].
• Two-tier bodies: ECPMP (complaints) and AECPMP (apex/review) [S2].
• ECPMPs are constituted by Pharmaceutical Associations, not by Government directly [S2].
• UCPMP covers medical representatives, promotional material, samples, gifts — comprehensive scope [S2].
• Penalty includes corrective statement in media for non-compliant promotional material [S2].
• Original UCPMP was first issued in 2012 as a voluntary code [S2].
• CCPA (under Consumer Protection Act, 2019) issued guidelines on misleading ads in 2024 [S4].

8. Mains Relevance

• GS-II: Governance — regulation of private sector; issues relating to health.
• GS-IV: Ethics in private institutions; corporate governance; probity.
• GS-III: Indian economy — pharmaceutical industry, IPR.
• Possible question stems:
• "The voluntary self-regulation model of UCPMP 2024 is inadequate to curb pharmaceutical malpractices. Critically examine."
• "Discuss the ethical dimensions of pharmaceutical marketing practices in India and the regulatory response of the State."
• "Examine how the UCPMP 2024 complements the existing legal framework — Drugs & Cosmetics Act, Income Tax Act, and Consumer Protection Act — in curbing pharma malpractices."

9. Related Topics to Study Next

• National Pharmaceutical Pricing Authority (NPPA) & DPCO — drug-pricing regulator.
• Drugs and Cosmetics Act, 1940 & New Drugs and Clinical Trials Rules, 2019 — quality/safety regulation.
• Central Drugs Standard Control Organisation (CDSCO) — drug regulator [S4 context].
• Consumer Protection Act, 2019 & CCPA — misleading ad jurisdiction [S4].
• Jan Aushadhi / PMBJP — affordability angle.
• National Medical Commission (NMC) regulations on professional conduct — doctor side of the freebie equation.
• Apex Laboratories v. DCIT (2022) — SC ruling on tax disallowance of freebies.
• Bulk Drug Parks / PLI for Pharma — industrial policy linkage.

10. Common Errors / Trap Areas

• UCPMP is NOT a statute — it is an executive code notified by DoP; aspirants often assume statutory backing.
• Implementing department is Department of Pharmaceuticals (DoP), not Ministry of Health & Family Welfare.
• ECPMPs are set up by industry associations, not by Government — a key self-regulation point.
• UCPMP regulates the pharma company side; doctor-side conduct is regulated by NMC, not UCPMP.
• The 2024 code is a revised/notified version — the 2012 code already existed as voluntary; don't call 2024 "the first" code.

11. Sources

• [S1] Measures to curb Malpractices in Pharma Companies — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2246062 — (tier 1)
• [S2] Uniform Code of Pharmaceuticals Marketing Practices 2024 to prevent unethical marketing — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2099707 — (tier 1)
• [S3] Year End Review 2024: Department of Pharmaceuticals — https://pib.gov.in/PressReleasePage.aspx?PRID=2090671 — (tier 1)
• [S4] Central Consumer Protection Authority Issues Guidelines on Misleading Advertisements — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2064963 — (tier 1)